Green Cross’ Elaprase Challenger Moves Ahead In US
This article was originally published in PharmAsia News
Executive Summary
Following a robust performance in the domestic market, Green Cross' Hunterase, the closest potential competitor to Shire's Hunter syndrome drug Elaprase, is set to enter mid-stage clinical trials in the US on its way to the world's biggest market with possible dosing and pricing advantages.